New trials, publications, preprints and grants on this target, month by month.
Publication
Complement-driven NETosis mediates immunotherapy resistance in STK11-mutant lung adenocarcinoma.
3 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC.
1 Nov 2026· Cancer letters· PUBMED
Trial
Chinese Multicenter Registry for Peutz-Jeghers Syndrome
1 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
LKB1 promotes lung adenocarcinoma cell senescence by suppressing the O-GlcNAc glycosylation-mediated activation of telomerase.
28 Sept 2026· Frontiers in pharmacology· PUBMED
Publication
Geraniin alleviates pathological visceral adipose tissue expansion through modulation of β-adrenergic receptor-associated cAMP-LKB1-AMPK signaling in high-fat diet-fed mice.
24 Sept 2026· Journal of ethnopharmacology· PUBMED
Publication
STK11 Adnexal Tumor: Expanding the Spectrum of Female Genital Tumors in Peutz-Jeghers Syndrome.
24 Sept 2026· Surgical pathology clinics· PUBMED
Publication
STK11 deficiency drives NSCLC immune resistance via ETNK2-mediated phosphoethanolamine accumulation.
16 Sept 2026· International immunology· PUBMED
Publication
Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer.
12 Sept 2026· The Journal of biological chemistry· PUBMED
Publication
STK11/LKB1 Loss in Cancer: From Developmental Constraint to Stress-Adapted Malignancy.
3 Sept 2026· Cancers· PUBMED
Publication
STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma.
1 Sept 2026· Cancer medicine· PUBMED
Preprint
Glutamine stress promotes metastatic potential via hexosamine biosynthetic pathway activity in KRAS/STK11-mutant lung adenocarcinoma.
27 Aug 2026· Research square· PUBMED
Publication
Targeting LKB1-inactivated lung cancers with a stapled peptide inhibitor of the CRTC-CREB pathway.
21 Aug 2026· Molecular therapy. Oncology· PUBMED
Publication
The LKB1-AMPK pathway in NAFLD: molecular mechanisms and therapeutic implications.
14 Aug 2026· Journal of physiology and biochemistry· PUBMED
Publication
GDD, a first-in-class APPL1 activator, restores mitochondrial homeostasis and insulin sensitivity with regulation of LKB1-AMPK axis.
11 Aug 2026· Phytomedicine : international journal of phytotherapy and phytopharmacology· PUBMED
Publication
STK11 c.1062 C > G germline variant in medullary thyroid carcinoma: implications for familial predisposition and genetic counseling.
3 Aug 2026· Endocrine· PUBMED
Publication
LKB1 Dysregulation in Duchenne Muscular Dystrophy Models: Disease Specificity and Epigenetic Control by HDAC Inhibitors.
1 Aug 2026· Annals of the New York Academy of Sciences· PUBMED
Publication
SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.
20 Jul 2026· Translational oncology· PUBMED
Trial
LKB1 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer: A Retrospective Cohort Study
17 Jul 2026· NA · ACTIVE_NOT_RECRUITING· CTGOV
Publication
Iron overload suppresses LKB1 and induces IL36G anti-tumor immunity in PDAC metastasis.
17 Jul 2026· Science advances· PUBMED
Publication
Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.
2 Jul 2026· Cancer immunology research· PUBMED
Publication
LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.
1 Jul 2026· Cancer discovery· PUBMED
Publication
Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer.
30 Jun 2026· Advances in therapy· PUBMED
Publication
LKB1 attenuates the transport activity of GLUT1 by regulating the alternative splicing of PKM1/PKM2 in cervical cancer.
16 Jun 2026· Journal of gynecologic oncology· PUBMED
Publication
Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.
12 Jun 2026· Cancer letters· PUBMED
Publication
PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC.
10 Jun 2026· Biomedical journal· PUBMED
Preprint
SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.
8 Jun 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer.
2 Jun 2026· Cell reports· PUBMED
Publication
Gene Expression Profiling of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 in Cell-Free RNA From Exhaled Breath Condensate: Diagnostic, Prognostic, and Therapeutic Implications in Advanced Lung Adenocarcinoma.
1 Jun 2026· Cancer reports (Hoboken, N.J.)· PUBMED
Publication
LKB1 Loss Sensitizes Lung Tumor Spheres to Mitomet-Induced Ferroptosis, and These Effects are Enhanced by mTOR Inhibition.
15 May 2026· Molecular carcinogenesis· PUBMED
Publication
Incidence and Prognostic Value of TP53, STK11, and KEAP1 Mutations Between De Novo Versus Recurrent Actionable Mutation-Negative Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.
8 May 2026· World journal of oncology· PUBMED